Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT01883921
Other study ID # BIS1-13-002
Secondary ID
Status Terminated
Phase
First received
Last updated
Start date June 2013
Est. completion date August 2019

Study information

Verified date August 2019
Source BriovaRx Infusion Services
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Primary:

- Demonstrate the utility of an electronic data capture (EDC) system (CareExchange™) using infusion nurse and patient measured physical, quality of life (QOL), respiratory, laboratory, and disability assessments in patients with Primary Immunodeficiency Disease (PIDD).

Secondary:

- Change in Intravenous/Subcutaneous Immunoglobulin (IVIg/SCIg) dose effects measured outcomes.

- Change in IVIg/SCIg dose timing effects measured outcomes.

- Change in patient status is reflected in measured outcomes.

- Assess the value to physicians from collected outcomes data.

- Identify types of patients by response to IVIg/SCIg therapies (well maintained, problematic, etc.).

- Change in response rate as measured by outcomes to IVIg/SCIg therapies by disease state, co-morbidities, and demographics.


Description:

This is a prospective, observational evaluation of immunoglobulin (Ig) therapy in consenting PIDD adult and assenting pediatric subjects who receive infusion services from BriovaRx Infusion Services (formerly AxelaCare Health Solutions, LLC). Subjects meeting all inclusion criteria who have provided informed consent/assent for trial participation will have validated, physician-prescribed, standard-of-care outcome measures, and Ig administration information recorded during normal home infusion visits. There will also be standard-of-care questions captured within some outcome measures recorded during normal home infusion visits that may be at a frequency and/or combination which may not be considered routine clinical care by some physicians who treat for this medical condition. Collected data will be de-identified and aggregated into cohorts of like diagnosis for trend analysis.


Recruitment information / eligibility

Status Terminated
Enrollment 1500
Est. completion date August 2019
Est. primary completion date August 2019
Accepts healthy volunteers No
Gender All
Age group 7 Years and older
Eligibility Inclusion Criteria:

- Diagnosis of any form of Primary Immunodeficiency Disease

- Age at enrollment = 7

- Sign informed consent/assented to participation

- Ability to read and write English

- Understanding of study procedures and ability to comply with study procedures for the entire length of the study

- Receiving Ig under the discretion of the patient's treating physician in accordance with standard treatment practices

- Have been on or is between doses of Ig under the discretion of the patient's treating physician in accordance with standard treatment practices

- Being considered to be prescribed Ig under the discretion of the patient's treating physician in accordance with standard treatment practices

- Determined to be eligible for infusion services by BriovaRx Infusion Services (formerly AxelaCare Health Solutions, LLC.) in collaboration with the patient's prescribing physician

Exclusion Criteria:

- Children (age = 6 years)

- Prisoners, and other wards of the state

- Determined to have non-competency of data collection requirements (physical assessments and use of an iPAD™) by the study participant's caregiver

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Immunoglobulin Therapy


Locations

Country Name City State
United States BriovaRx Infusion Services Lenexa Kansas

Sponsors (1)

Lead Sponsor Collaborator
BriovaRx Infusion Services

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Analysis of collected data captured in CareExchange™ -ability to show and track changes in outcome data in PIDD patients. Up to 5 Years
Secondary Physician feedback will demonstrate if having real-time access to patient data captured during a home infusion will assist in the management of the patient's disease. Up to 5 Years
Secondary Response rate for those receiving IVIg/SCIg therapies. Up to 5 Years
Secondary Exhibit differences in response rate of IVIg/SCIg therapies across disease states and demographics Up to 5 Years
Secondary Measure variables within patients who receive IVIg/SCIg therapies Up to 5 Years
See also
  Status Clinical Trial Phase
Completed NCT03939533 - Study to Monitor Subcutaneous Human Immunoglobulin Administered at Modified Dosing Regimens in Patients With Primary Immunodeficiency Diseases Phase 3
Recruiting NCT03266640 - Virus Specific Cytotoxic T-Lymphocytes (CTLs) for Refractory Cytomegalovirus (CMV) Phase 2
Recruiting NCT03266627 - Adenovirus-specific Cytotoxic T-lymphocytes for Refractory Adenovirus Infection Phase 2
Completed NCT01859754 - Octagam 5% Versus Comparator Post Marketing Trial
Recruiting NCT03148028 - Immunological Characteristics of Patients With PID and IBD N/A
Active, not recruiting NCT04354818 - Coronavirus (COVID-19) Outcomes Registries in Immunocompromised Individuals Australia (CORIA)
Completed NCT03988426 - Study to Evaluate the Efficacy, Tolerability and Safety of Octanorm in Patients With Primary Immunodeficiency Diseases Phase 3
Completed NCT01888484 - Study of Octanorm Subcutaneous IG in Patients With PID Phase 3
Completed NCT01131858 - Study of Vitamin D3 Substitution to Patients With Primary Immunodeficiency Phase 1/Phase 2
Completed NCT03211689 - The Impact of Exercise on Stress, Fatigue, and Quality of Life in Individuals With Primary Immunodeficiency Disease N/A
Recruiting NCT03266653 - EBV-specific Cytotoxic T-lymphocytes (CTLs) for Refractory EBV Infection Phase 2
Completed NCT02327351 - TCR Alpha/Beta Depletion for HSCT From Haploidentical and Unrelated Donors in the Treatment of PID Phase 2/Phase 3
Completed NCT03618147 - Primary Immunodeficiency in Kuwait
Recruiting NCT04197596 - Treatment of Refractory BK Infections With Related Donor BK Specific Cytotoxic T-cells (CTLs) Phase 1/Phase 2
Recruiting NCT03422614 - Pathophysiology of Inborn Immunodeficiencies N/A
Completed NCT02888535 - Intensive Care Unit and Secondary and Primary Immune Deficiency
Recruiting NCT04232085 - Reduced Intensity BMT for Immune Dysregulatory and Bone Marrow Failure Syndromes Using Post-Transplant Cyclophosphamide Phase 2
Active, not recruiting NCT03037359 - A Study About Low Blood Pressure in Patients With Primary Immunodeficiency Disease Treated With Immune Globulin Products
Completed NCT03069079 - Investigation of Dental Health in Children With Neutrophil Defects: A Clinical Study N/A
Recruiting NCT03414528 - Identification of New Inborn Errors of Immunity N/A